Spelman, Timothy
Herring, William L.
Zhang, Yuanhui
Tempest, Michael
Pearson, Isobel
Freudensprung, Ulrich
Acosta, Carlos http://orcid.org/0000-0002-7257-8675
Dort, Thibaut
Hyde, Robert
Havrdova, Eva
Horakova, Dana
Trojano, Maria
De Luca, Giovanna
Lugaresi, Alessandra
Izquierdo, Guillermo
Grammond, Pierre
Duquette, Pierre
Alroughani, Raed
Pucci, Eugenio
Granella, Franco
Lechner-Scott, Jeannette
Sola, Patrizia
Ferraro, Diana
Grand’Maison, Francois
Terzi, Murat
Rozsa, Csilla
Boz, Cavit
Hupperts, Raymond
Van Pesch, Vincent
Oreja-Guevara, Celia
van der Walt, Anneke
Jokubaitis, Vilija G.
Kalincik, Tomas
Butzkueven, Helmut
Spelman, T
Havrdova, E
Horakova, D
Trojano, M
Luca, G
Lugaresi, A
Izquierdo, G
Grammond, P
Duquette, P
Alroughani, R
Pucci, E
Granella, F
Lechner-Scott, J
Sola, P
Ferraro, D
Grand’Maison, F.
Terzi, M
Rozsa, C
Boz, C
Hupperts, R
Van Pesch, V
Oreja-Guevara, C
van der Walt, A
Jokubaitis, V. G.
Kalincik, T
Butzkueven, H
,
Funding for this research was provided by:
Biogen International GmbH
Article History
Accepted: 12 October 2021
First Online: 18 December 2021
Change Date: 6 January 2022
Change Type: Update
Change Details: The word document with the supplementary information has been corrected.
Declarations
:
: Timothy Spelman is a statistical contractor for the MSBase Foundation and has received compensation for serving on advisory boards for Biogen and speaker honoraria from Novartis and Roche. William L. Herring, Yuanhui Zhang, and Isobel Pearson are employees of RTI Health Solutions, an independent non-profit research organisation, which received funding pursuant to a contract with Biogen. Michael Tempest, Ulrich Freudensprung, Carlos Acosta, and Robert Hyde are employees of Biogen and hold shares or stocks from Biogen as part of their remuneration. Thibaut Dort was an employee and shareholder of Biogen at the time of his passing. Eva Havrdova has received honoraria and research support from Biogen, Merck Serono, Novartis, Roche, and Teva; has served in advisory boards for Actelion, Biogen, Celgene, Merck Serono, Novartis, and Sanofi Genzyme; and has been supported by the Czech Ministry of Education research project PROGRES Q27/LF1. Dana Horakova has received speaker honoraria and consulting fees from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva and has received support for research activities from Biogen and the Czech Ministry of Education (project Progres Q27/LF1). Maria Trojano has served on scientific advisory boards for Biogen, Novartis, Roche, and Merck; has received speaker honoraria from Biogen, Sanofi, Merck, Roche, Teva, and Novartis; and has received research grants for her Department from Biogen, Merck, Roche, and Novartis. Giovanna De Luca has served on scientific advisory boards for Merck, Biogen, Novartis, Roche, and Sanofi Genzyme and has received funding for travel and speaker honoraria from Biogen, Merck, Novartis, Sanofi Genzyme, and Roche. Alessandra Lugaresi has received personal compensation for consulting, serving on a scientific advisory board, speaking or other activities from Biogen, Merck Serono, Mylan, Novartis, Roche, Sanofi/Genzyme, and Teva. Her institutions have received research grants from Novartis. Guillermo Izquierdo has received speaking honoraria from Almirall, Biogen, Merck, Novartis, Roche, Sanofi, and Teva. Pierre Grammond has served in advisory boards for Novartis, EMD Serono, Roche, Biogen, Sanofi Genzyme, and Pendopharm and has received grant support from Genzyme and Roche; his institution has also received research grants from Biogen, Sanofi Genzyme, and EMD Serono. Pierre Duquette has received support for organised continuing medical education activities and travel fees to attend advisory meetings from Biogen, EMD Serono, Genzyme, and Novartis. Raed Alroughani has received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche, Sanofi, and Genzyme. Eugenio Pucci has received travel grants from Roche, Novartis, Merck, Genzyme-Sanofi, Biogen, and Teva and received equipment from <i>Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche</i>. Franco Granella has received research funding from Biogen and Sanofi Genzyme; fees for advisory boards and speaker honoraria from Biogen, Merck Serono, Novartis, Roche, and Sanofi Genzyme; and travel funding from Biogen, Merck Serono, Roche, and Sanofi Genzyme. Jeannette Lechner-Scott has accepted travel compensation from Novartis, Biogen, and Merck Serono; her institution receives the honoraria for talks and advisory board commitments as well as research grants from Biogen Merck, Roche, TEVA, and Novartis. Patrizia Sola has served on scientific advisory boards for Biogen and Teva; has received funding for travel and speaker honoraria from Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, and Teva; and has received research grants for her institution from Bayer, Biogen, Merck, Novartis, Sanofi, and Teva. Diana Ferraro has received travel funding or speaker honoraria from Merck, Biogen, Sanofi, Novartis, Teva, and Roche and has served on advisory boards for Biogen, Merck, Novartis, Sanofi, and Roche. Francois Grand’Maison has received honoraria or research funding from Biogen, Genzyme, Mitsubishi, Novartis, Ono Pharmaceuticals, and Teva Neuroscience. Murat Terzi has received travel grants from Merck & Co., Novartis, Bayer-Schering, and Teva Pharmaceutical Industries and has participated in clinical trials by Sanofi-Aventis, Roche, and Novartis. Csilla Rozsa has received speakers’ honoraria from Biogen, Merck Serono, Roche, and Sanofi Genzyme; travel grants from Biogen, Merck, and Sanofi Genzyme; and fees for advisory boards from Biogen, Merck Serono, Novartis, and Teva. Cavit Boz has received conference travel support from Biogen, Novartis, Bayer-Schering, Merck, and Teva. Raymond Hupperts has received nurse support from Merck and Sanofi and has served on advisory boards for Sanofi, Biogen, and Roche. Vincent Van Pesch has received travel grants from Merck, Biogen, Sanofi, Bristol Meyer Squibb, Almirall, and Roche. His institution has received research grants and consultancy fees from Roche, Biogen, Sanofi, Bristol Meyer Squibb, Merck, Almirall, and Novartis Pharma. Celia Oreja-Guevara has received honoraria for speaking and consulting fees from Biogen, Celgene, Alexion, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. Anneke van der Walt is an employee of Monash University and has accepted travel compensation from Merck, Biogen, and Roche; she has received honoraria for talks, steering committee activities, and research grants from Roche, Merck, Biogen, and Novartis. Vilija Jokubaitis is an employee of Monash University; she has accepted travel compensation from Biogen, Merck, and Roche and speakers’ honoraria from Biogen and Roche. Tomas Kalincik has served on scientific advisory boards for Roche, Sanofi Genzyme, Novartis, Merck, and Biogen and a steering committee for the Brain Atrophy Initiative supported by Sanofi Genzyme; has received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva, BioCSL, and Merck; and has received research support from Biogen. Helmut Butzkueven is an employee of Monash University and has accepted travel compensation from Merck, Biogen, and Roche; his institution receives honoraria for talks, steering committee activities, and research grants from Roche, Merck, Biogen, Genzyme, Novartis, and Medday Pharma.
: Informed consent from all patients according to local laws is required for participation in MSBase, and the project has received human research ethics committee approval or an exemption at each contributing centre.